Patent · US Active

Cabergoline derivatives

US9012640B2 · kind B2 · utility

14Cited by
102References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 22, 2012
Grant dateApr 21, 2015
Priority date—
Expiry dateAug 8, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D457/06
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B receptor and 5-HT2C receptors the using the compounds and compositions disclosed herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.